U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 69

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated **April 16, 2015,**
1. Saint Francis Medical Center	3. License No. 24-00158-03 is amended in its entirety to read as follows:
2. 211 Saint Francis Drive Cape Girardeau, Missouri 63703	4. Expiration Date: September 30, 2015
	5. Docket No. 030-02269 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed sources (Medi-Physics OncoSeed Model 6711 and EchoSeed Model 6733)	D. 150 millicuries
E. Any byproduct material permitted by 10 CFR 35.500	E. Sealed sources (North American Scientific Model No. 3601 or DuPont Pharma Model No. NES 8412)	E. 600 millicuries
F. Any byproduct material permitted by 10 CFR 31.11	F. Prepackaged kits	F. 2 millicuries

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
24-00158-03

Docket or Reference No.
030-02269

Amendment No. 69

E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

F. *In vitro* studies.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 211 St. Francis Drive, Cape Girardeau, Missouri.

11. The Radiation Safety Officer (RSO) for this license is Mark Gates, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized User	Material and Use
Willeford J. Stoecker, M.D.	10 CFR 35.100, 35.200, 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries), and 35.500.
Craig W. Williams, M.D.	10 CFR 35.100, 35.200, 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries), and 35.500.
Kenneth Retter, M.D.	10 CFR 35.200 and 35.500.
Tappan Roy, M.D.	10 CFR 35.300 and 10 CFR 35.400 (limited to iodine-125).
Mark Lewis Pfautsch, D.O.	10 CFR 35.100, 35.200, 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries), and 35.500.
Mark L. Gates, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
George A. Pjura, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Theodore R. Swartz, M.D.	10 CFR 35.100, 35.200, and 35.500.
David A. Law, M.D.	10 CFR 35.200.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
24-00158-03

Docket or Reference No.
030-02269

Amendment No. 69

Authorized User	Material and Use
Bryan S. Beck, M.D.	10 CFR 35.200.
Jagannohan R. Alinani, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11.
Rajinder M. Gulati, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500, and 31.11.
Tom Brumitt, M.D.	10 CFR 35.100, 35.200, and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).
James Borders, M.D.	10 CFR 35.100, 35.200, and 35.500.
Huan Nguyen, M.D.	10 CFR 35.100, 35.200, and 35.500.
Christopher Russell, M.D.	10 CFR 35.100, 35.200, and 35.500.
Andrew E. West, M.D.	10 CFR 35.100, 35.200, and 35.500.
Cedric Strange, M.D.	10 CFR 35.100, 35.200, and 35.500.
Paul H. Holcomb, M.D.	10 CFR 35.200.
Veena D. Divecha, M.D.	10 CFR 35.300.
Carl R. Jenson , M.D.	10 CFR 35.300.
Derek L. Fimmen, M.D.	10 CFR 35.200.
Shanaree M. Muzinich, M.D.	10 CFR 35.200.
Jeffrey Wichman, M.D.	10 CFR 35.200.
Evan Moser, D.O.	10 CFR 35.200.
Thomas D. Hodgkiss, M.D.	**10 CFR 35.100 and 35.200.**

13. The licensee may transport licensed material or deliver licensed material to a carrier for transport in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
24-00158-03

Docket or Reference No.
030-02269

Amendment No. 69

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated March 29, 2005 (excluding references to QMP and written directives);

B. Letters dated March 16, 2005, September 23, 2005 (includes facsimile-transmitted document also dated September 23, 2005), August 25, 2006, May 5, 2011, June 26, 2012, and August 27, 2012;

C. Letter received November 2, 2006 (with attachments); and

D. Facsimile letter dated January 11, 2007 (with attachments).

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date JUN 17 2015

By _____

Bryan A. Parker
Materials Licensing Branch
Region III